Skip to main content

Table 2 Multivariate Cox analyses of PFS, OS and CSS in patients received AHT

From: Androgen receptor splice variant 7 detected by immunohistochemical is an independent poor prognostic marker in men receiving adjuvant androgen-deprivation therapy after radical prostatectomy

Variables

Outcomes

Multivariate analysis

HR (95% CI)

P-value

Age at diagnosis (ref: < 65.0 years)

Age ≥ 65.0 years

PFS

1.17 (0.50–2.71)

0.717

OS

3.04 (0.62–14.93)

0.169

CSS

4.27 (0.45–40.00)

0.204

Gleason score at diagnosis (ref: 6≤ G ≤ 7)

Gleason score ≥ 8

PFS

0.62 (0.25–1.58)

0.317

OS

1.70 (0.39–7.46)

0.483

CSS

3.02 (0.43–20.83)

0.265

Total prostate-specific antigen (ng/ml) (ref: < 20)

PSA ≥ 20

PFS

1.06 (0.46–2.48)

0.887

OS

1.32 (0.29–6.06)

0.721

CSS

1.20 (0.12–11.76)

0.878

Pathological T stage at diagnosis (ref: T2)

T3,4

PFS

3.53 (1.39–9.01)

0.008

OS

0.72 (0.15–3.50)

0.682

CSS

0.98 (0.10–9.35)

0.987

Pathological N stage at diagnosis (ref: N0)

N1

PFS

1.75 (0.73–4.18)

0.210

OS

1.92 (0.46–8.06)

0.371

CSS

0.81 (0.08–8.62)

0.862

AR-V7-positive (ref: AR-V7-negative)

PFS

3.76 (1.63–8.70)

0.002

OS

4.81 (1.28–17.86)

0.020

CSS

9.17 (1.48–55.56)

0.017

R1(ref: R0)

PFS

2.02 (0.80–5.08)

0.135

OS

1.79 (0.38–8.47)

0.465

CSS

0.51 (0.04–7.35)

0.620

  1. AHT adjuvant hormonal therapy, PSA prostate specific antigen, PFS progression-free survival, OS overall survival, CSS cancer-special survival. P-values less than 0.05 are highlighted in bold